-
公开(公告)号：JP2010022372A
公开(公告)日：2010-02-04
申请号：JP2009205660
申请日：2009-09-07
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
IPC: C07K16/18 , C12N15/09 , A61K38/16 , A61K39/395 , A61P35/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/63 , C12P21/00 , C12P21/08 , G01N33/53
CPC classification number: C07K16/464 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2851 , C07K16/3061 , C07K2317/20 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules for treating NHL (non-Hodgkin lymphoma), repeatedly usable and easily and efficiently producible. SOLUTION: There is provided an antibody containing at least one CDR (Complementarity Determining Region) derived from a mouse monoclonal antibody having specificity for CD22. Also provided is a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further provided are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and use of the antibody molecules in the treatment of diseases mediated by cells expressing CD22. COPYRIGHT: (C)2010,JPO&INPIT
Abstract translation: 要解决的问题：提供用于治疗NHL（非霍奇金淋巴瘤）的抗体分子，可重复使用且容易且高效地生产。 解决方案：提供了含有至少一种衍生自对CD22具有特异性的小鼠单克隆抗体的CDR（互补决定区）的抗体。 还提供了CDR移植抗体，其中至少一个CDR是修饰的CDR。 还提供了编码抗体分子链，载体，转化的宿主细胞的链DNA序列和抗体分子在治疗由表达CD22的细胞介导的疾病中的用途。 版权所有（C）2010，JPO＆INPIT
-
公开(公告)号：JP2013230158A
公开(公告)日：2013-11-14
申请号：JP2013140245
申请日：2013-07-04
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
IPC: C07K16/18 , C12N15/09 , A61K31/7088 , A61K38/16 , A61K39/395 , A61K45/00 , A61K48/00 , A61P35/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/63 , C12P21/00 , C12P21/08
CPC classification number: C07K16/464 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2851 , C07K16/3061 , C07K2317/20 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules for treating NHL, capable of being repeatedly used and easily and efficiently produced.SOLUTION: An antibody containing at least one CDR obtained from a mouse monoclonal antibody having specificity to CD22 is disclosed. A CDR transplanted antibody, wherein at least one CDR is a modified CDR, is also disclosed. Furthermore, a DNA sequence encoding chains of antibody molecules, a vector, transformed host cells and use of the antibody molecules in the treatment of diseases mediated with CD22 expressing cells are disclosed.
Abstract translation: 要解决的问题：提供用于治疗NHL的抗体分子，能够重复使用并且容易且有效地产生。解决方案：公开了含有至少一种CDR的抗体，其具有对CD22特异性的小鼠单克隆抗体。 还公开了CDR移植抗体，其中至少一个CDR是经修饰的CDR。 此外，公开了编码抗体分子链，载体，转化的宿主细胞的DNA序列和抗体分子在用CD22表达细胞介导的疾病的治疗中的用途。
-
公开(公告)号：NO336201B1
公开(公告)日：2015-06-15
申请号：NO20044742
申请日：2004-11-02
Applicant: UCB PHARMA SA
Abstract: SAMMENDRAG Oppfinnelsen vedrører antistoffmolekyler inneholdende minst ett CDR avledet fra et mus monoklonalt antistoff med spesifisitet for humant CD22. Oppfinnelsen vedrører også et CDR-podet antistoff hvor minst ett av CDR'ene er et modifisert CDR. Videre vedrører oppfinnelsen DNA-sekvenser som koder for kjedene til antistoffmolekylene, vektorer, transformerte vertsceller og anvendelser av antistoffmolekylene for behandling av sykdommer mediert ved celler som uttrykker CD22.
-
4.发明专利
-
公开(公告)号：SG161744A1
公开(公告)日：2010-06-29
申请号：SG2006084065
申请日：2003-05-02
Applicant: UCB PHARMA SA
IPC: C07K16/18 , A61K38/16 , A61K39/395 , A61P35/00 , C07K16/28 , C12N15/13 , C12N15/63 , C12P21/00 , A61K31/7088 , C12N5/10 , C12N15/85
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
Patent Agency Ranking
公开(公告)号：DE60331910D1
公开(公告)日：2010-05-12
申请号：DE60331910
申请日：2003-05-02
Applicant: UCB PHARMA SA
IPC: C07K16/18 , C07K16/28 , A61K31/7088 , A61K38/16 , A61K39/395 , A61P35/00 , C12N5/10 , C12N15/13 , C12N15/63 , C12N15/85 , C12P21/00
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
-
公开(公告)号：ES2341708T3
公开(公告)日：2010-06-25
申请号：ES03718974
申请日：2003-05-02
Applicant: UCB PHARMA SA
IPC: C07K16/18 , C07K16/28 , A61K31/7088 , A61K38/16 , A61K39/395 , A61P35/00 , C12N5/10 , C12N15/13 , C12N15/63 , C12N15/85 , C12P21/00
Abstract: Una molécula de anticuerpo que tiene especificidad para el CD22 humano, que comprende una cadena pesada en la que el dominio variable comprende la SEQ ID NO: 1 para CDR-H1, la secuencia GINPGNNYATYRRKFQG de gH7 de la Figura 6 o la SEQ ID NO: 2 o la SEQ ID NO: 13 o la SEQ ID NO: 15 o la SEQ ID NO: 16 para CDR-H2, y la SEQ ID NO: 3 para CDR-H3, y una cadena ligera en la que el dominio variable comprende la SEQ ID NO: 4 para CDR-L1, la SEQ ID NO: 5 para CDR-L2 y la SEQ ID NO: 6 para CDR-L3.
-
公开(公告)号：AT462729T
公开(公告)日：2010-04-15
申请号：AT03718974
申请日：2003-05-02
Applicant: UCB PHARMA SA
IPC: C07K16/18 , C07K16/28 , A61K31/7088 , A61K38/16 , A61K39/395 , A61P35/00 , C12N5/10 , C12N15/13 , C12N15/63 , C12N15/85 , C12P21/00
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
公开(公告)号：HK1071762A1
公开(公告)日：2005-07-29
申请号：HK05104462
申请日：2005-05-27
Applicant: UCB PHARMA SA
IPC: C07K16/18 , A61K20060101 , A61K38/16 , A61K39/395 , A61P20060101 , A61P35/00 , C07K20060101 , C07K16/28 , C12N20060101 , C12N15/13 , C12N15/63 , C12P21/00
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.022 seconds)
